RAMIRO DE LEON: Open Payments
NPI 1467736868 · MCALLEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$682 in 42 payments from 12 companies in 2025. Trend: 2023 $1,302 · 2024 $947 · 2025 $682
Food & beverage: $682
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $258 |
| Amgen Inc. | 5 | $85 |
| AstraZeneca Pharmaceuticals LP | 3 | $62 |
| GlaxoSmithKline, LLC. | 3 | $55 |
| Corcept Therapeutics | 2 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Lilly USA, LLC | 1 | $26 |
| SANOFI PASTEUR INC. | 1 | $20 |
Products named: Wegovy, OTEZLA, Ozempic, SHINGRIX, Korlym, FARXIGA, JARDIANCE, GEMTESA.
Industry payments across TX — which companies pay providers there.
